期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2型糖尿病治疗新药物:GLP-1类似物 被引量：7

下载PDF
导出
摘要 肠胰升血糖素样肽1(GLP-1)作为一种疗效显著的二型糖尿病治疗药物,但体内半衰期过短,限制了其在临床上的应用。因此,科研人员在GLP-1原有的结构基础上进行改造,产生了疗效类似但半衰期显著增长的GLP-1类似物,其中以利拉鲁肽较为有代表性。
作者 魏玉敏 王琪 邬金迪
机构地区 哈尔滨医科大学附属第一医院精神卫生中心药局
出处 《航空航天医药》 2010年第10期1868-1869,共2页 Aerospace Medicine
关键词 二型糖尿病(T2DM) GLP-1 GLP-1类似物 利拉鲁肽
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献2

二级参考文献31

  • 1梁延平.抗糖尿病药物的研究进展[J].现代中西医结合杂志,2005,14(13):1792-1795. 被引量：9
  • 2姜文清,吴学军,邹定,马捷,李金娥.抗糖尿病新药格鲁辛胰岛素[J].中国新药杂志,2006,15(6):478-480. 被引量：3
  • 3颜云湘.第3代磺脲类抗糖尿病药——格列美脲片[J].中国临床药学杂志,2006,15(5):334-335. 被引量：48
  • 4陈卫琼.糖尿病口服药物概况[J].现代医药卫生,2007,23(9):1328-1329. 被引量：1
  • 5黄建权,傅得兴,胡欣,张君仁.抗糖尿病药物维达列汀[J].中国新药杂志,2007,16(6):486-488. 被引量：11
  • 6傅勇,李蓬秋.GLP-1抗糖尿病作用研究进展[J].实用糖尿病杂志,2007,3(3):53-55. 被引量：8
  • 7Kieffer,T.J.,McIntosh,C.H.S,Pederson R.A.Degradation of glucose-dependent Insulinotropic poly peptide and truncated glucagon-like peptide 1 in vitro and in vitro by dipeptidylpeptidase IV.Endocrinology 1995;136:3585-3596.
  • 8Hoist JJ,Orskov C,Nieleen OV,et al.Truncated ghcagonslike peptide I,an insulin-releasing hormone from the distal gut.FEBS Lett,1987 Jan 26;211(2):169-174.
  • 9Nauck MA,Heimesaat MM.Behle K.et al.Efleets of glucagon-like peptide 1 on counterregulatory hormone responses.cognitive functions,and insulin secretion during hyperinsulinemic,stepped hypoglyeemic clamp experiments in healthy volunteers.J Clin Endocrinol Metab 2002;87:1239-1246.
  • 10Widmann C,Dolci W.Thorens B.Internalization and homologous desensitization of the GLP-1 Receptor depend on phosphorylation of the receptor carboxyl tail at the same three Sites[J].diabetes 2001:50:2237-2243.

共引文献15

同被引文献34

  • 1Kristin Taylor,.Kate Gurney ,Jenny Han. Exenafide once week- ly treatment maintained improvements in glycemic control and weight loss over 2 years[ J]. BMC Endocrine Disorders ,2011, 11:9.
  • 2Ilaria Dicembrini, Laura Pala, CarloMaria Rotella. From Theo- ry to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors [ J ]. Therapy Experimental Diabetes Re- search,2011:8.
  • 3Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:insulin resistance and b cell function from fasting plasma glucose and insulin concentrations in man [ J ]. Diabetologia, 1985,28:412- 419.
  • 4张月华.GLP-1及其类似物与2型糖尿病的关系.1008-5041(2010)11-0921-04:921-924.
  • 5Davies R, Donnelly AH, Barnett S, et al. Kilcoyn. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes:re- suits of the Helping Evaluate Exenatide in patients with diabe- tes compared with Long-Acting insulin (HEELA) study [ J ]. Diabetes, Obesity and Metabolism,2009,11 : 1153-1162.
  • 6Craig W, Spellman. Incorporating Glucagon-like Peptide-1 Re- ceptor Agonists Into Clinical Practice [ J ]. JAOA, 2012,112 : s7-s15.
  • 7Ratner D, Maggs LL, Nielsen AH. et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weiglat mefformin-uv.atedpatients with type 2 diabetes mellitus [ J ]. Diabetes, Obesity and Metabolism,2006, 8:419-428.
  • 8Valentine W J, Palmer A J, Lammert M ,et al. Evaluating the long- term cost-effectiveness of liraglutide versus exenatide BID in pa- tients with type 2 diabetes who fail to improve with oral antidiabetic agents[ J]. Clin Ther,2011,33(11) :1698-1712.
  • 9Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-I analogue, LiragIutide, vs glibene|amide mono-therapy in Japanese patients with type 2 diabetes[J]. Curr Med Res Opin,2010(26) :1013-1022.
  • 10Ryan G J,Foster K T,Jobe L J. Review of the therapeutic uses of liraglutide[ J]. Clin Ther,2011,33(7) :793-811.

引证文献7

二级引证文献19

航空航天医药
2010年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部